IsoPSA leads to reduction in prostate biopsy recommendations
“The idea is to develop strategies that reduce the likelihood of needing a biopsy or improving the sensitivity of the biopsy to find a high-grade cancer, one that's treatable,” says Eric A. Klein, MD.
In this video, Eric A. Klein, MD, gives an overview of the recent Urology Practice study “IsoPSA reduces provider recommendations for biopsy and magnetic resonance imaging in men with total prostate specific antigen ≥4 ng/mL: a real-world observational clinical utility study," for which he served as senior author. Klein is Emeritus Professor and Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.
